Literature DB >> 27746264

Repeated-measure analyses: Which one? A survey of statistical models and recommendations for reporting.

Jacques P Maurissen1, Thomas J Vidmar2.   

Abstract

Repeated-measure analysis of variance is a general term that can imply a number of different statistical models used to analyze data from studies in which measurements are taken from each subject on more than one occasion. Repeated-measure analyses encompass univariate models (with or without sphericity adjustment), multivariate models, mixed models, analysis of covariance, multilevel models, latent growth models, and hybrids of these models. These models are based on different assumptions, especially regarding correlations (sphericity) between within-subject factors, which comprise the variance-covariance matrix. Violation of this assumption may lead to misleading and erroneous conclusions. Because many papers do not provide enough information about what analysis was really conducted, and about why it was done, the reader is unable to evaluate the validity of the analysis. Here a brief overview of several of the most commonly used models for analyzing data from repeated-measure designs is provided, and guidance is suggested for describing the statistical approach employed. The goals of this paper are (1) to give authors an overview of the diversity of commonly used models and associated assumptions, and (2) to facilitate reporting sufficient information about the tests to allow the reader to evaluate the validity of the tests and the credibility of the inferences made by the authors. Among the available approaches to repeated-measure analyses, the mixed model is recommended for its flexibility in handling different covariance structures and its insensitivity to missing data. Whether or not it is used, the overall guiding principles in reporting should always be Accuracy, Completeness, and Transparency (ACT principles): tell the reader precisely all what you did and why.
Copyright © 2016 Elsevier Inc. All rights reserved.

Keywords:  Accuracy, completeness, transparency; Repeated-measure analysis of variance; Reporting recommendations; Type I and II errors; Univariate, multivariate, mixed effects; Variance/covariance matrix

Mesh:

Year:  2016        PMID: 27746264     DOI: 10.1016/j.ntt.2016.10.003

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  5 in total

1.  Detection of water-molecular-motion configuration in patients with lupus nephritis: a primary study using diffusion-weighted imaging.

Authors:  Huilan Shi; Yanyan Wang; Tiekun Yan; Junya Jia; Dong Li; Li Wei; Wenya Shang; Zhenfeng Zheng
Journal:  BMC Nephrol       Date:  2020-07-29       Impact factor: 2.388

2.  Prognostic value of perioperative NT-proBNP after corrective surgery for pediatric congenital heart defects.

Authors:  Fangqin Lin; Lingling Zheng; Yanqin Cui; Weidan Chen; Ramit Kumar Gupta; Huixian Li; Xinxin Chen; Huimin Xia; Huiying Liang
Journal:  BMC Pediatr       Date:  2019-12-16       Impact factor: 2.125

3.  A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats.

Authors:  Yewei Wang; Dandan Wang; Yan Chen; Xinyu Fang; Lingfang Yu; Chen Zhang
Journal:  Int J Neuropsychopharmacol       Date:  2020-11-26       Impact factor: 5.176

4.  Coaching-Based Teleoccupational Guidance for Home-Based Stroke Survivors and Their Family Caregivers: Study Protocol for a Superior Randomized Controlled Trial.

Authors:  Li Zhang; Yanning Yan; Zengxin Sun; Xinjing Ge; Xiaolu Qin; Keh-Chung Lin
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-22       Impact factor: 2.650

5.  Long-term physical activity on prescription intervention for patients with insufficient physical activity level-a randomized controlled trial.

Authors:  Stefan Lundqvist; Mats Börjesson; Åsa Cider; Lars Hagberg; Camilla Bylin Ottehall; Johan Sjöström; Maria E H Larsson
Journal:  Trials       Date:  2020-09-15       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.